Photo from wikipedia
We sought to replace full‐dose Gd‐DTPA with safer and lower‐dose contrast agents for delayed gadolinium‐enhanced MRI of cartilage (dGEMRIC). Gd‐BOPTA has a lower intrinsic nephrogenic systemic fibrosis risk and a… Click to show full abstract
We sought to replace full‐dose Gd‐DTPA with safer and lower‐dose contrast agents for delayed gadolinium‐enhanced MRI of cartilage (dGEMRIC). Gd‐BOPTA has a lower intrinsic nephrogenic systemic fibrosis risk and a 2‐fold higher relaxivity at 3T; thus, the contrast agent dose may be halved, further reducing contrast agent‐dependent risks.
Keywords:
mri cartilage;
gadolinium enhanced;
delayed gadolinium;
dose dtpa;
enhanced mri;
dose
Journal Title: Journal of Magnetic Resonance Imaging
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Magnetic Resonance Imaging
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!